VTYX insider buying and SEC filings, explained
Ventyx Biosciences, Inc. · CIK 1851194
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$463K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Dec 18, 2025 | Sale | Raju Mohan (CEO and Director) sold 47,345 shares at about $7.72 ($366K). Holdings down 2% to 2,372,863 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
| Dec 18, 2025 | Sale | John Nuss (Chief Scientific Officer) sold 12,675 shares at about $7.72 ($98K). Holdings down 3% to 489,481 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
15 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow VTYX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.